Health Data Analytics Institute Announces an Advanced Suite of Predictors and a Series of Strategic Collaborations with Leading Healthcare Organizations


BOSTON, Mass. – March 3, 2020 – Health Data Analytics Institute (HDAI) — a startup focused on delivering insights that transform patient care — today introduced an application programming interface (API) that provides access to their platform for predicting clinical complications, avoidable hospital admissions, and other outcomes. HDAI is collaborating with Cleveland Clinic, Houston Methodist, and New England Baptist Hospital on separate projects aimed at measuring the impact of HDAI’s validated, predictive platform on clinical decision-making and patient outcomes.

With HDAI’s API, health systems and physician groups can use a full suite of validated predictors to help clinicians deliver better care by giving them individualized risk profiles of their patients in real-time. The risk models will also be provided to select academic researchers requiring tools to adjust for patient comorbidities and other characteristics, as well as to study outcomes over time.

“Our goal is to democratize access to artificial intelligence (AI) in healthcare, to make it available and as easy to use for as many organizations and individuals as possible,” said Nassib Chamoun, founder and CEO of Health Data Analytics Institute. “Over the last year, healthcare providers have dramatically increased their investment in deploying AI. We’re focused on helping these organizations scale quickly without taking on unnecessary work. Our API-accessible platform delivers a suite of risk predictors, developed using more than 100 billion de-identified patient encounters. Client teams can load recent clinical data for individual patients or defined populations into our models to generate detailed, real-time risk profiles that can support better clinical decisions and more appropriate resource allocation.”

HDAI is collaborating with a range of healthcare institutions and is in the process of recruiting additional organizations. Most recently, HDAI received funding from the Robert Wood Johnson Foundation to support a project to analyze current and future demand for long-term care and to develop an API for clinical and health services researchers. HDAI is also working with New England Baptist Hospital to study the effectiveness of surgical and nonsurgical options for spinal procedures; with Cleveland Clinic on using AI to match patients with the appropriate level of presurgical support; and with Houston Methodist on testing potential clinical applications that would utilize HDAI’s risk predictors.

“What’s compelling about HDAI — even beyond the high relevance and calibration of their models based on the breadth and depth of the underlying data — is their pragmatic focus on applying AI to help improve clinical practice today, not in a distant future,” said Philippe Amouyal, managing director at Invus, a lead investor in HDAI. “Our involvement with HDAI stems from our belief that their platform has the potential to become a fundamental analytics layer that improves care by providing a rigorous quantification of patient risk to inform clinical judgment.”

The announcement of HDAI’s API and strategic partnerships comes on the heels of recent news that the Centers for Medicare and Medicaid Services (CMS) selected HDAI as one of the 25 participants — out of more than 300 applicants — to advance to the second phase of the AI Health Outcomes Challenge. The Challenge is a national initiative to harness healthcare’s collective creativity to develop better ways of predicting and preventing unplanned admissions and complications. CMS is slated to announce the seven finalists in the Challenge in April. In addition, HDAI recently raised a Series B round in July 2019 to deploy and scale their predictive risk modeling platform. Leading investors include Invus, Harry McPike, and several other prominent individuals.

HDAI’s founder and CEO, Nassib Chamoun, is a serial entrepreneur who founded Aspect Medical Systems, which was later sold to Covidien and whose product remains the standard for measuring the effects of anesthesia during surgery. Collectively, the HDAI team has deployed healthcare technologies that have impacted the lives of millions of patients and published hundreds of evidence-based studies and abstracts related to the application of data science in health and medicine.


Chamoun spoke on a panel at HIMSS 2020 with Google Cloud and Nuance Communications. The focus of the HIMSS panel was: Reactions from the Field — Artificial Intelligence and Machine Learning.



Health Data Analytics Institute (HDAI) is an analytics company with a validated, predictive platform for measuring short- and long-term clinical risks. Our platform provides accurate healthcare predictors built on extensive underlying data assets unlocked by a sophisticated risk modeling methodology refined over 20 years. We work with progressive health systems, physician groups, and life sciences companies to support the development of effective and targeted treatments, the delivery of higher-quality patient care, and the provision of appropriate services for populations. For more information, please visit: HDAI.


The Invus Group (Invus) is an evergreen equity investment platform with more than $8 billion of capital and principal offices in New York, Paris, and Hong Kong. The firm partners with owner-managers who aspire to transform their industries. For more information, please visit:


Harry McPike has been actively trading in the global financial markets for more than 30 years using quantitative research methods to develop sophisticated trading strategies and is a global private investor with a focus on finance and technology sector opportunities.


Media Contact:

KT McGraw


Your privacy matters

We believe that an individual’s meaningful control over their own data is as valuable as the data itself. That’s why we are committed to protecting privacy at every turn.
We always:
  • Provide transparency about the information we collect and why we collect it
  • Comply with all applicable privacy rules and regulations
  • Delete personal data from our servers if an individual opts out
We never:
  • Sell data to third parties
  • Share data with third parties besides the primary, explicitly authorized institution
  • Collect data besides what is disclosed
  • Keep personal data for individuals who have opted out

We speak legalese only when we have to, but we do our best to keep it human. Provided below are the full versions of our Privacy Policy and Terms of Service. If you have any questions, don’t hesitate to contact us for clarification.